Cheah, C. Y., Chihara, D., Horowitz, S., Sevin, A., Oki, Y., Zhou, S., . . . Fanale, M. A. (2016). Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol.
استشهاد بنمط شيكاغوCheah, C. Y., et al. "Patients With Classical Hodgkin Lymphoma Experiencing Disease Progression After Treatment With Brentuximab Vedotin Have Poor Outcomes." Ann Oncol 2016.
MLA استشهادCheah, C. Y., et al. "Patients With Classical Hodgkin Lymphoma Experiencing Disease Progression After Treatment With Brentuximab Vedotin Have Poor Outcomes." Ann Oncol 2016.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.